Neurocrine Biosciences, Inc. (NBIX) Q4 2017 Earnings Results

Neurocrine Biosciences Misses on EPS, Stock Up 1.85%

Neurocrine Biosciences reported a lower-than-expected EPS, which typically raises concerns among investors. However, the stock rose by 1.85%, suggesting that investors may be optimistic about the company's future prospects and ongoing projects. The lack of revenue details and guidance may leave some uncertainty, but management's positive outlook on their pipeline could be driving the stock's upward movement.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.07	N/A	-66.42%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism despite the EPS miss. They emphasized their commitment to advancing their pipeline.

Management highlighted ongoing development efforts and future potential.

They acknowledged the challenges faced in the quarter but remain focused on long-term goals.

Neurocrine Biosciences Misses on EPS, Stock Up 1.85%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Misses on EPS, Stock Up 1.85%

Key numbers

Management commentary